Costs of mass drug administration for scabies in Fiji.

• Published in: PLOS Neglected Tropical Diseases
• Main Authors: Maria Mow, Li Jun Thean, Matthew Parnaby, Jyotishna Mani, Eric Rafai, Aalisha Sahukhan, Mike Kama, Meciusela Tuicakau, Joseph Kado, Lucia Romani, Daniel Engelman, Margot Whitfeld, John Kaldor, Andrew Steer, Natalie Carvalho
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2022
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Public aspects of medicine; RA1-1270; Arctic; Murdoch
• Online Access: https://doi.org/10.1371/journal.pntd.0010147; https://doaj.org/article/b819545c6aa84b73a75669b939d69746

In 2019, the Murdoch Children's Research Institute in partnership with the Fiji Ministry of Health and Medical Services carried out an integrated mass drug administration (MDA) for the treatment of scabies and lymphatic filariasis in the Northern Division of Fiji (population estimate 131,914). We conducted a retrospective micro-costing exercise focused on the cost of scabies control in order to inform budgeting and policy decision making in an endemic setting. We collected detailed information on financial and economic costs incurred by both parties during the course of the MDA campaign (April 2018 to July 2019). We also conducted interviews with personnel involved in the financial administration of the MDA campaign. The economic cost of delivering two doses of ivermectin was US$4.88 per person. The cost of donated drugs accounted for 36.3% of total MDA costs. In this first large-scale MDA for the public health control of scabies, the estimated cost of delivering MDA per person for scabies was considerably more expensive than the costs reported for other neglected tropical diseases. The important cost drivers included the remuneration of health care workers who were extensively involved in the campaign, coverage of hard-to-reach, mainly rural populations and the two-dose regimen of ivermectin. These results highlight the importance of these cost determinants and can be used to plan current and future MDA programs.